IDORSIA LTD TWELVE MONTHS 2016 PRO-FORMA FINANCIAL INFORMATION.
|
|
- Linette Johns
- 6 years ago
- Views:
Transcription
1 1 IDORSIA LTD TWELVE MONTHS 2016 PRO-FORMA FINANCIAL INFORMATION.
2 2 CONTENTS 03 UNAUDITED CONSOLIDATED PRO-FORMA FINANCIAL INFORMATION OF THE IDORSIA GROUP AS OF AND FOR THE TWELVE MONTH PERIOD ENDED 31 DECEMBER AUDITORS ASSURANCE REPORT
3 3 UNAUDITED CONSOLIDATED PRO-FORMA FINANCIAL INFORMATION OF THE IDORSIA GROUP FOR THE TWELVE MONTH PERIOD ENDED 31 DECEMBER 2016 UNAUDITED CONSOLIDATED PRO-FORMA INCOME STATEMENTS Twelve months ended 31 December 2016 (in CHF thousands, except per share amounts) Actelion Ltd (historical) Pro-Forma adjustments Idorsia Ltd (pro-forma) (audited) (unaudited) (unaudited) Net revenue Product sales 2,412,198 (2,412,198) - Contract revenue 5,740 (5,740) - Total net revenue 2,417,938 (2,417,938) - Operating (expenses) 1 Cost of sales 2 (245,537) 245,537 - Research and development (568,534) 285,915 (282,619) Selling, general and administration (760,158) 719,959 (40,199) Amortization of acquired intangible assets (54,997) 54,997 - Total operating (expenses) (1,629,226) 1,306,408 (322,818) Operating income 788,712 (1,111,530) (322,818) Interest income (expense), net 1,183 (1,318) (135) Interest on loan - (13,239) (13,239) Other financial income (expense), net 2,539 (3,041) (502) Total financial income (expense) 3,722 (17,598) (13,876) Income before income tax benefit (expense) 792,434 (1,129,128) (336,694) Income tax benefit (expense) (97,599) 97,599 - Net income 694,835 (1,031,529) (336,694) Less: Net loss attributable to the noncontrolling interests 1,551-1,551 Net income attributable to shareholders 696,386 (1,031,529) (335,143) Basic net income per share attributable to shareholders 6.66 n.m. 3 (2.81) Weighted-average number of common shares (in thousands) 104,626 n.m ,123 Diluted net income per share attributable to shareholders 6.46 n.m. 3 (2.81) Weighted-average number of common shares (in thousands) 107,811 n.m ,123 1 Includes share-based compensation as follows: Research and development (27,199) 10,359 (16,840) Selling, general and administration (38,025) 31,319 (6,706) Total share-based compensation (65,224) 41,678 (23,546) 2 Excludes amortization of intangible assets as presented separately. 3 Not meaningful
4 4 UNAUDITED CONSOLIDATED PRO-FORMA BALANCE SHEET (in CHF thousands, except number of shares) ASSETS Notes 31 December 2016 Actelion Ltd Pro-Forma Idorsia Ltd (historical) adjustments (pro-forma) (audited) (unaudited) (unaudited) Current assets Cash and cash equivalents 3 495, , ,979 Trade and other receivables, net 445,868 (443,018) 2,850 Inventories 135,820 (135,820) - Other current assets 115,763 (93,367) 22,396 Total current assets 1,192,831 (439,606) 753,225 Noncurrent assets Property, plant and equipment, net 4 350,215 (191,790) 158,425 Intangible assets, net 382,705 (382,705) - Goodwill 135,048 (135,048) - Deferred tax assets 20,528 (20,528) - Other noncurrent assets 25,150 (21,677) 3,473 Total noncurrent assets 913,646 (751,748) 161,898 TOTAL ASSETS 2,106,477 (1,191,354) 915,123 LIABILITIES Current liabilities Trade and other payables 83,009 (72,304) 10,705 Accrued expenses 5 445,730 (390,982) 54,748 Other current liabilities 40,211 (39,787) 424 Total current liabilities 568,950 (503,073) 65,877 Noncurrent liabilities Convertible loan 6-293, ,422 Pension liability 7 66,427 (37,120) 29,307 Contingent considerations 115,630 (115,630) - Other noncurrent liabilities 34,312 (15,764) 18,548 Total noncurrent liabilities 216, , ,277 Total liabilities 785,319 (378,165) 407,154 EQUITY Shareholders' equity 8 Common shares issued 53,881 (47,925) 5,956 Additional paid-in capital - 841, ,495 Accumulated profit (loss) 2,187,889 (2,523,032) (335,143) Treasury shares, at cost (680,053) 680,053 - Accumulated other comprehensive income (loss) (236,220) 236,220 - Total shareholders' equity 1,325,497 (813,189) 512,308 Equity attributable to noncontrolling interests 9 (4,339) - (4,339) Total equity 1,321,158 (813,189) 507,969 TOTAL LIABILITIES AND EQUITY 2,106,477 (1,191,354) 915,123
5 5 NOTES TO UNAUDITED CONSOLIDATED PRO-FORMA FINANCIAL INFORMATION FOR THE TWELVE MONTH PERIOD ENDED 31 DECEMBER 2016 (CHF thousands, except share and per share amounts) NOTE 1. Overview The unaudited consolidated pro-forma financial information of Idorsia Ltd ( Idorsia ) as at and for the period ended 31 December 2016 (the Pro-Forma Financial Information ) is based upon and should be read in conjunction with the historical consolidated financial statements of Actelion Ltd as at and for the period ended 31 December The Pro-Forma Financial Information has been prepared to illustrate the effect of the Demerger in connection with the Transaction between Actelion Ltd and Janssen Holding GmbH, an indirect subsidiary of Johnson & Johnson ( J&J ). The following expressions have the meaning as defined in the Prospectus: Demerger, Reorganization, Demerger Distribution, Listing and Settlement. The Pro-Forma Financial Information simulates the effect of the following events of the Demerger: The Reorganization, as if it had taken place on 31 December 2015; The Demerger Distribution and the Listing of Idorsia, as if they had taken place on1 January The Pro-Forma Financial Information has been prepared for the sole purpose of inclusion in the Prospectus in order to list the ordinary shares of Idorsia in the stock market organized and managed by SIX. Because of its nature, the Pro-Forma Financial Information may be affected by important factors and consequently Idorsia s financial position or results of operations as at and for the twelve month period ended 31 December 2016 may differ materially from the Pro- Forma Financial Information. The Pro-Forma Financial Information does not purport to be indicative of Idorsia s future performance or its financial position and results of operations as the Transactions will only take place at the Settlement expected in the course of the second quarter of NOTE 2. Basis of preparation The Pro-Forma Financial Information has been prepared using consistent accounting policies with those applied in the preparation of the consolidated financial statements of Actelion Ltd as of and for a twelve month period ended 31 December The Pro-Forma Financial Information and pro-forma adjustments are based on available information and certain assumptions and estimates that Management of Idorsia believes are reasonable, of which: Balance sheet Idorsia would be funded at the date of the Demerger Distribution with a gross and net cash position of CHF 1.0 billion of which CHF 420 million resulting from the Reorganization, CHF 580 million resulting from a convertible loan ( Convertible Loan ) provided by Cilag Holding AG ( Cilag ), an indirect subsidiary of J&J; Property, plant and equipment would have been transferred to Idorsia in connection with the Reorganization at their tax value of CHF 167 million; The first tranche of CHF 135 million of the Convertible Loan would have automatically converted on 5 January 2016 resulting in the creation of 11'793'220 new shares of Idorsia; Cilag would not have elected for the conversion of any further tranche of the CHF 445 million of the Convertible Loan before 31 December 2016;
6 6 Idorsia would not have drawn down from the Credit Facility for the CHF equivalent of USD 250 million, during the twelve month period ended 31 December The effect of the currency translation adjustment from the consolidation of foreign subsidiaries and the effects of actuarial gains and/or losses related to pensions accounted for in other comprehensive income would not be material. Based on all available evidence, Idorsia would record a full valuation allowance on deferred tax assets from operating loss carryforwards. Income statement Expenses relating to employees that are expected to join Idorsia at the Settlement would have been incurred on the same terms then prevailing at Actelion from 1 January 2016 to 31 December 2016, such costs mainly consisting of fix salary, bonus, social and pension plan benefits and long term incentives of share-based compensation; General and administrative ( G&A ) expenses other than expenses relating to employees have been prorated based on the allocation of employees between Actelion and Idorsia as agreed upon between J&J and Idorsia; Expenses and revenues from the transitional service agreements that will be rendered after the Settlement between Actelion and Idorsia have not been taken into account as they are not material; Expenses relating to Drug Discovery have been fully allocated to Idorsia as the whole research organization is transferred to Idorsia; Expenses relating to Clinical Development have been allocated based on the compounds of the clinical pipeline transferred to Idorsia in connection with the Reorganization, as if these costs would have been incurred on the same terms then prevailing at Actelion from 1 January 2016 to 31 December 2016; Depreciation in connection with property, plant and equipment transferred would have been at the same level as recognized in the consolidated financial statements of Actelion Ltd for the twelve month period ended 31 December 2016; Vaxxilon would have been consolidated in Idorsia as if the 73.9% equity stake in Vaxxilon would have been transferred to Idorsia on 31 December NOTE 3. Cash and cash equivalents At31December 2016, the gross cash position of CHF 728 million would have consisted of: the initial CHF 420 million resulting from the Reorganization; plus the initial CHF 580 million resulting from the Convertible Loan; less the cash out-flow of CHF 272 million.
7 7 The following table reflects the cash flow for the twelve month period ended 31 December 2016: Twelve months ended (in CHF thousands) 31 December 2016 (unaudited) Cash flow from operating activities Net income (336,694) Adjustments to reconcile net income to net cash provided from operating activities: Depreciation 18,121 Share-based compensation 23,546 Interest on loan 13,239 Changes in operating assets and liabilities: Trade and other receivables 273 Trade and other payables - Accrued expenses 21,262 Other operating cash flow items (3,085) Net cash flow provided by (used in) operating activities (263,338) Cash flow from investing activities Purchase of property, plant and equipment (8,683) Purchase of intangible assets - Net cash flow provided by (used in) investing activities (8,683) Cash flow from financing activities Convertible loan - Equity increase - Net cash flow provided by (used in) financing activities - Net effect of exchange rates on cash and cash equivalents - Net change in cash and cash equivalents (272,021) Cash and cash equivalents at beginning of period 1,000,000 Cash and cash equivalents at end of period 727,979 NOTE 4. Property, plant and equipment Property, plant and equipment of CHF 158 million would mainly have consisted of: the buildings in Allschwil (Hegenheimermattweg 89 and Gewerbestrasse 6) transferred to Idorsia as part of the Reorganization for their tax value of CHF 127 million; equipment, mainly laboratory equipment, transferred to Idorsia as part of the Reorganization for their tax value of CHF 40 million; depreciation of CHF 18 million; capital expenditure of CHF 9 million. NOTE 5. Accrued expenses At 31 December 2016, a total amount of CHF 55 million operating expenses would have been accrued mainly consisting of: Personnel and compensation costs of CHF 26 million; Research and development costs of CHF 17 million; Other accrued expenses of CHF 12 million.
8 8 NOTE 6. Convertible loan The convertible loan of CHF 293 million would have consisted of: the nominal amount of CHF 445 million of the outstanding 10-year convertible debt; less the initial discount of CHF 165 million, calculated by using an interest rate based on a 10 year Swiss interest-bearing straight bond, which management believes does not materially differ from the accounting policy for convertible debt as defined in the Prospectus; plus interest expenses on loan of CHF 13 million. The convertible loan will accrete from CHF 293 million to CHF 445 million over the remaining term of the loan (9 years). NOTE 7. Pension Pension liability was estimated at CHF 29 million which would have consisted of: the projected defined benefit obligation of CHF 197 million in respect of the allocation of employees from Actelion to Idorsia; less the fair value of plan assets of CHF 168 million. NOTE 8. Shareholders' equity The following table reflects the effect of changes in shareholders equity: Common shares (in CHF thousands, except number of shares) Shares Amount Shareholders equity Additional paid-in capital Accumulated profit (loss) Noncontrolling interests Equity attributable to noncontrolling interests Total equity At 1 January 2016 (unaudited) 107,330,210 5, ,722 - (2,788) 521,301 Comprehensive income (loss): Net income (335,143) (1,551) (336,694) Other comprehensive income (loss) Comprehensive income (loss) (335,143) (1,551) (336,694) Convertible equity 11,793, , ,425 Convertible loan premium , ,391 Share-based compensation expense , ,546 At 31 December 2016 (unaudited) 119,123,430 5, ,495 (335,143) (4,339) 507,969 Share Capital The share capital of CHF 5,956,172 ( shares with a par value of CHF 0.05 each) would have consisted of: an initial shares with a par value of CHF 0.05 each issued as part of the Reorganization for a total amount of CHF 5,366,510.50; an additional shares with a par value of CHF 0.05 each issued to Cilag resulting from the conversion of the first tranche of CHF 135 million of the Convertible Loan on 5 January 2016.
9 9 Additional paid-in capital The additional paid-in capital of CHF 841 million would have consisted of: an initial paid-in capital of CHF 519 million mainly resulting from the contribution of CHF 420 million cash and CHF 167 million property, plant and equipment, less net liabilities transferred to Idorsia; a CHF 299 million impact of the convertible loan, including the equity component from the issuance of the convertible loan and the conversion premium of the conversion of the first tranche of the convertible loan; a CHF 24 million impact relating to share-based compensation expense; NOTE 9. Equity attributable to noncontrolling interests At 31 December 2016 the equity attributable to noncontrolling interests of CHF 4 million would have consisted of the contributions of the noncontrolling interests less the loss attributable to Vaxxilon s minority shareholders. NOTE 10. Commitments and guarantees At 31 December 2016 Idorsia would have had the main following commitments: future minimum lease payments under non-cancelable operating leases at 31 December 2016 would have amounted to CHF 75 million; low single-digit royalty payments as well as additional potential payments of up to EUR 41.3 million upon achievement of predefined development, approval and commercialization milestones to Max-Planck Innovation GmbH in connection with Vaxxilon; funding commitment s of up to the CHF equivalent of EUR 19.4 million to Vaxxilon contingent upon successful completion of predefined clinical and development milestones; upon exercise of an option with ReveraGen Biopharma Inc. they would be entitled to receive up to USD 165 million in development and regulatory milestones and up to USD 190 million for further indications depending on achievement of certain development, regulatory approval and commercialization milestones; support of R&D activities up to a maximum amount of USD 1 million p.a. paid to ReveraGen Biopharma Inc. for the next twenty-eight months unless earlier terminated or extended. At 31 December 2016 Idorsia would have had the main following guarantees: a guarantee relating to operating leases for subsidiaries in foreign jurisdictions of CHF 1 million. The Pro-Forma Financial Information was approved by the board of directors of Idorsia Ltd on 2 June On behalf of the Board of Directors of Idorsia Ltd Jean-Pierre Garnier Chairman of the board of directors Jean-Paul Clozel Board member and Chief Executive Officer
Financial Report NINE-MONTH REPORT
Financial Report 20 18 NINE-MONTH REPORT The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help
More informationCONSOLIDATED US GAAP FINANCIAL STATEMENTS FOR MARCH 31, 2017
CONSOLIDATED US GAAP FINANCIAL STATEMENTS FOR MARCH 31, 2017 Contents: CONSOLIDATED INCOME STATEMENTS CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME CONSOLIDATED BALANCE SHEETS CONSOLIDATED STATEMENTS
More informationIdorsia Financial Report
0 Idorsia Financial Report as of 30 September 2017 Contents 3 11 Financial review Interim unaudited consolidated financial statements 3 Financial review Idorsia s key numbers Profit and loss Period ended
More informationCONSOLIDATED US GAAP FINANCIAL STATEMENTS FOR SEPTEMBER 30, 2016
CONSOLIDATED US GAAP FINANCIAL STATEMENTS FOR SEPTEMBER 30, 2016 Contents: CONSOLIDATED INCOME STATEMENTS CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME CONSOLIDATED BALANCE SHEETS CONSOLIDATED STATEMENTS
More informationFinancial Report FIRST QUARTER REPORT
Financial Report 20 18 FIRST QUARTER REPORT The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to
More informationFinancial Report FIRST QUARTER
Financial Report 20 FIRST QUARTER 19 The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more
More informationFinancial Report HALF YEAR REPORT
Financial Report 20 18 HALF YEAR REPORT The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help
More informationIdorsia Interim Consolidated Financial Statements Half Year 2017
0 Idorsia Interim Consolidated Financial Statements Half Year 2017 1 Interim Consolidated Financial Statements Consolidated Income Statement Period ended June 30, (in CHF thousands, except per share amounts)
More informationConsolidated Balance Sheets Consolidated Balance Sheet
Consolidated Balance Sheets Consolidated Balance Sheet As of 2017 2016 Current Assets Cash and cash equivalents $ 12,681 $ 9,968 Short-term investments 30,338 18,664 Trade receivables 30,662 19,788 Other
More informationSoftchoice Corporation. Consolidated Financial Statements March 31, 2003 (in thousands of Canadian dollars)
Consolidated Financial Statements (in thousands of Canadian dollars) Consolidated Balance Sheets (in thousands of Canadian dollars) ASSETS Current assets December 31, (audited) Cash and cash equivalents
More informationEdwards Lifesciences Corporation Unaudited Consolidated Statements of Operations
Unaudited Consolidated Statements of Operations Three Months Ended March 31, (in millions, except per share data) 2003 2002 Net sales $212.5 $162.3 Cost of goods sold 89.1 69.1 Gross profit 123.4 93.2
More informationCompensation Report ANNUAL REPORT
Report 20 17 ANNUAL REPORT The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients. We have more ideas, we see more opportunities and we want to help more patients.
More informationACTELION LTD FIRST QUARTER 2015 FINANCIAL REPORT.
ACTELION LTD FIRST QUARTER 2015 FINANCIAL REPORT. APRIL 21, 2015 2 CONTENTS 03 FIRST QUARTER 2015 FINANCIAL REVIEW 15 UNAUDITED FIRST QUARTER 2015 CONSOLIDATED FINANCIAL STATEMENTS Disclaimer and notes
More informationABB Ltd Interim Consolidated Income Statements (unaudited) Six months ended
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Jun. 30, 2012 Jun. 30, 2011 Jun. 30, 2012 Jun. 30, 2011 Sales of products 15'501 15'207 8'078 8'154
More informationASPEED TECHNOLOGY INC. AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS (In Thousands of New Taiwan Dollars) June 30, 2018 December 31, 2017 (Audited) June 30, 2017 June 30, 2018 December 31, 2017 (Audited) June 30, 2017 ASSETS Amount % Amount %
More informationCentral Maine Power Company and Subsidiaries. Consolidated Financial Statements (Unaudited) For the Three Months Ended March 31, 2018 and 2017
Central Maine Power Company and Subsidiaries Consolidated Financial Statements (Unaudited) For the Three Months Ended March 31, 2018 and 2017 Table of Contents March 31, 2018 and 2017 Financial Statements
More informationConsolidated Balance Sheets
page 77 Consolidated Balance Sheets Toyota Motor Corporation March 31, 2011 and 2012 ASSETS 2011 2012 2012 Current assets Cash and cash equivalents 2,080,709 1,679,200 $ 20,431 Time deposits 203,874 80,301
More informationPORTLAND GENERAL ELECTRIC COMPANY AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME (In millions, except per share amounts) (Unaudited)
CONSOLIDATED STATEMENTS OF INCOME (In millions, except per share amounts) Years Ended December 31, Revenues: Revenues, net $ 1,988 $ 2,009 Alternative revenue programs, net of amortization 3 Total Revenues
More informationDigital River, Inc. First Quarter Results (In thousands, except share data) Subject to reclassification
(In thousands, except share data) Consolidated Balance Sheets (Unaudited) December 31, Assets Current assets Cash and cash equivalents $ 500,742 $ 542,851 Short-term investments 144,615 162,794 Accounts
More informationABB Ltd Interim Consolidated Income Statements (unaudited)
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Dec. 31, 2014 Dec. 31, 2013 Dec. 31, 2014 Dec. 31, 2013 Sales of products 33,279 35,282 8,545 9,549
More informationAGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) (Unaudited)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) Twelve Months Ended October 31, Percent 2002 2001 Inc/(Dec) Orders $ 6,013 $ 6,414 (6%) Net revenue $ 6,010 $ 8,396
More informationRITE AID CORPORATION AND SUBSIDIARIES. CONSOLIDATED BALANCE SHEETS (Dollars in thousands) (unaudited)
CONSOLIDATED BALANCE SHEETS (Dollars in thousands) March 3, 2018 ASSETS Current assets: Cash and cash equivalents $ 132,468 $ 447,334 Accounts receivable, net 2,039,605 1,869,100 Inventories, net of LIFO
More informationABB Ltd Interim Consolidated Income Statements (unaudited)
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Sep. 30, 2014 Sep. 30, 2013 Sep. 30, 2014 Sep. 30, 2013 Sales of products 24,734 25,733 8,255 8,948
More informationCONSOLIDATED BALANCE SHEETS(Pro-Forma) DECEMBER 31, 2009 AND 2008 (In Thousands of New Taiwan Dollars, Except Par Value)
AIRTAC INTERNATIONAL GROUP AND SUBSIDIARIES CONSOLIDATED BALANCE SHEETS(Pro-Forma) DECEMBER 31, 2009 AND 2008 (In Thousands of New Taiwan Dollars, Except Par Value) Code Assets Amount % Amount % Code Liabilities
More informationFINANCIAL STATEMENTS
FINANCIAL STATEMENTS Consolidated Income Statement 35 Consolidated Statement of Comprehensive Income 36 Consolidated Statement of Financial Position 37 Consolidated Statement of Changes In Equity 38 Consolidated
More information(In millions, except share amounts which are reflected in thousands and per share amounts) March 28, 2009
UNAUDITED COND ENSED CONSOLIDATED STATEMENTS OF OPERATIONS (In millions, except share amounts which are reflected in thousands and per share amounts) Three Months Ended Six Months Ended March 28, 2009
More informationASSETS As of March 31, 2014 (000's Except shares and per share amounts)
Exhibit 99.3 UNAUDITED PRO FORMA CONDENSED CONSOLIDATED FINANCIAL STATEMENTS ASSETS As of March 31, 2014 (000's Except shares and per share amounts) GPS SecureAlert Global Adjustments Consolidated CURRENT
More informationInterim Report Q4 FY 17
Interim Report Q4 FY 17 Quarter 4 / Fiscal Year 2017 Sustained positive development Sivantos delivered 3.1% organic growth 1) in Q4 FY2017. The moderate growth rate compared to previous quarters was a
More informationEMC CORPORATION Consolidated Income Statements (in thousands, except per share amounts) Unaudited
Consolidated Income Statements (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2011 2010 2011 2010 Revenues: Product
More informationUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS. (In millions, except share amounts) ASSETS:
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except share amounts) ASSETS: April 1, September 24, 2006 2005 Current assets: Cash and cash equivalents $6,346 $3,491 Short-term investments
More informationConsolidated Balance Sheets
Consolidated Balance Sheets March 31 2015 2016 2016 Assets: Current assets Cash and cash equivalents 726,888 600,897 $ 5,317,673 Marketable securities 19,033 28,012 247,894 Notes and accounts receivable:
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) December 31, 2015 December 31, 2014 December 31, 2015 December 31, 2014 Revenues: Subscription $ 244,702
More informationRITE AID CORPORATION AND SUBSIDIARIES. CONSOLIDATED BALANCE SHEETS (Dollars in thousands) (unaudited)
CONSOLIDATED BALANCE SHEETS (Dollars in thousands) March 3, 2018 ASSETS Current assets: Cash and cash equivalents $ 147,092 $ 447,334 Accounts receivable, net 1,908,955 1,869,100 Inventories, net of LIFO
More informationDigital River, Inc. Second Quarter Results (Unaudited, in thousands) Subject to reclassification
(Unaudited, in thousands) Condensed Consolidated Balance Sheets As of December 31, 2008 2007 Assets: Current assets Cash and cash equivalents $ 276,927 $ 381,788 Short-term investments 201,297 315,636
More informationInterim Report Q2 FY 18
Interim Report Q2 FY 18 Quarter 2 / Fiscal Year 2018 Strong revenue growth driven by Signia Nx Sivantos delivered a strong organic growth 1) of 9.8% in Q2 2018 while nominal growth at 3.6% accounted negative
More informationUNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS. (In millions, except share amounts) ASSETS:
UNAUDITED CONDENSED CONSOLIDATED BALANCE SHEETS (In millions, except share amounts) ASSETS: July 1, September 24, 2006 2005 Current assets: Cash and cash equivalents $8,013 $3,491 Short-term investments
More informationSelling, general and administrative expenses 35,645 33,787. Net other operating income (292) (270) Operating profit 44,202 17,756
Condensed Interim Consolidated Income Statement For the quarter ended September 30 Continuing operations Revenue 328,071 258,941 Cost of sales 248,516 207,668 Gross profit 79,555 51,273 Selling, general
More informationInterim Report Q1 FY 18
Interim Report Q1 FY 18 Quarter 1 / Fiscal Year 2018 Continued positive development extends into the new fiscal year Sivantos delivered 3.5% organic growth 1) in Q1 2018 with negative Fx translation effects
More informationSales $ 407,444 $ 396,064 $ 1,602,580 $ 1,515,608 Cost of sales (258,660) (242,460) (1,021,230) (952,221)
CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (Dollar amounts in thousands, except per share data) 2018 2017 2018 2017 Sales $ 407,444 $ 396,064 $ 1,602,580 $ 1,515,608 Cost of sales (258,660) (242,460)
More informationRITE AID CORPORATION AND SUBSIDIARIES. CONSOLIDATED BALANCE SHEETS (Dollars in thousands) (unaudited)
CONSOLIDATED BALANCE SHEETS (Dollars in thousands) ASSETS Current assets: Cash and cash equivalents $ 447,334 $ 245,410 Accounts receivable, net 1,869,100 1,771,126 Inventories, net of LIFO reserve of
More informationTE CONNECTIVITY LTD. CONSOLIDATED STATEMENTS OF OPERATIONS (UNAUDITED)
CONSOLIDATED STATEMENTS OF OPERATIONS For the Quarters Ended For the Nine Months Ended June 26, June 27, June 26, June 27, 2015 2014 2015 2014 (in millions, except per share data) Net sales $ 3,118 $ 3,075
More informationInterim Report Q4 FY 16
Interim Report Q4 FY 16 Innovation continues to drive strong performance Sivantos continued its strong performance across all three regions in Q4 2016. The performance of a strong product portfolio (eg.
More informationITURAN LOCATION AND CONTROL LTD. Consolidated Interim Financial Statements as of June 30, 2017
Consolidated Interim Financial Statements as of June 30, 2017 Consolidated Financial Statements as of June 30, 2017 Table of Contents Page Consolidated Interim Financial Statements: Balance Sheets 2-3
More informationConnecticut Natural Gas Corporation. Financial Statements (Unaudited) June 2007
Financial Statements (Unaudited) June 2007 Statements of Income (Unaudited) Three Months Six Months Periods ended June 30 2007 2006 2007 2006 Operating Revenues Sales and services $58,882 $61,057 $248,468
More informationFinancial Statement Balance Sheet
Financial Statement Balance Sheet Page 1 of 1 Financial Statement Balance Sheet Accounting Title 2014/09/30 2013/12/31 2013/09/30 Balance Sheet Assets Current assets Cash and cash equivalents Total cash
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Revenues: Subscription $ 166,751 $ 104,878 $ 567,217 $ 349,804 Professional services and other 31,253 20,352
More informationABB Ltd Interim Consolidated Income Statements (unaudited) Year ended
ABB Ltd Interim Consolidated Income Statements (unaudited) ($ in millions, except per share data in $) Dec. 31, 2013 Dec. 31, 2012 Dec. 31, 2013 Dec. 31, 2012 Sales of products 35,282 32,979 9,549 9,251
More informationEMC CORPORATION Consolidated Income Statements (in thousands, except per share amounts) Unaudited
EMC CORPORATION Consolidated Income Statements (in thousands, except per share amounts) Three Months Ended Twelve Months Ended December 31, December 31, December 31, December 31, 2011 2010 2011 2010 Revenues:
More informationDELL INC. Condensed Consolidated Statement of Income and Related Financial Highlights (in millions, except per share data and percentages) (unaudited)
Condensed Consolidated Statement of Income and Related Financial Highlights (in millions, except per share data and percentages) Three Months Ended % Growth Rates 2013 2012 Yr. to Yr. Net revenue Products
More informationMERGE HEALTHCARE INCORP ORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
MERGE HEALTHCARE INCORP ORATED AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands) 2012 2011 (unaudited) (unaudited) Current assets: Cash and cash equivalents, including restricted cash
More informationConsolidated Balance Sheets
Consolidated Balance Sheets March 31, 2008 and 2009 ASSETS 2008 2009 2009 Current assets Cash and cash equivalents... 1,628,547 2,444,280 $ 24,883 Time deposits... 134,773 45,178 460 Marketable securities...
More informationIndependent Accountants Review Report
Independent Accountants Review Report The Board of Directors Acer Incorporated: We have reviewed the non-consolidated balance sheets of Acer Incorporated as of September 30, 2008 and 2007, and the related
More informationYasheng Group 2010 Financial Results
Yasheng Group 2010 Financial Results CONSOLIDATED BALANCE SHEETS 2010 2009 2008 ASSETS 849,454,265 739,630,043 736,213,299 Current assets: Cash and cash equivalents 10,116,750 8,010,017 7,880,338 Accounts
More informationJABIL CIRCUIT, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS
CONDENSED CONSOLIDATED BALANCE SHEETS (In thousands) 2011 2010 ASSETS Current assets: Cash and cash equivalents $ 888,611 $ 744,329 Trade accounts receivable, net 1,100,926 1,408,319 Inventories 2,227,339
More informationRITE AID CORPORATION AND SUBSIDIARIES. CONSOLIDATED BALANCE SHEETS (Dollars in thousands) (unaudited)
CONSOLIDATED BALANCE SHEETS (Dollars in thousands) March 3, 2018 ASSETS Current assets: Cash and cash equivalents $ 410,043 $ 447,334 Accounts receivable, net 1,717,830 1,869,100 Inventories, net of LIFO
More informationIndependent Auditors Report
Independent Auditors Report The Board of Directors Acer Incorporated: We have audited the accompanying non-consolidated balance sheets of Acer Incorporated (the Company ) as of June 30, 2012 and 2011,
More informationPORTLAND GENERAL ELECTRIC COMPANY AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME
CONDENSED CONSOLIDATED STATEMENTS OF INCOME AND COMPREHENSIVE INCOME (Dollars in millions, except per share amounts) Three Months Ended Nine Months Ended 2017 2016 2017 2016 Revenues, net $ 515 $ 484 $
More informationFINANCE REPORT. INTERACTIVE ANNUAL REPORT 2016
INTERACTIVE ANNUAL REPORT 2016 Our mission: treat more patients with groundbreaking medicines Actelion Ltd. is a leading biopharmaceutical company focused on the discovery, development and commercialization
More informationPORTLAND GENERAL ELECTRIC COMPANY AND SUBSIDIARIES CONSOLIDATED STATEMENTS OF INCOME
CONSOLIDATED STATEMENTS OF INCOME (Dollars in millions, except per share amounts) Revenues, net $ 2,009 $ 1,923 $ 1,898 Operating expenses: Purchased power and fuel 592 617 661 Generation, transmission
More informationDANA HOLDING CORPORATION Quarterly Financial Information and Reconciliations of Non-GAAP Financial Measures
Quarterly Financial Information and Reconciliations of Non-GAAP Financial Measures Non-GAAP Financial Measures Adjusted EBITDA is a non-gaap financial measure which we have defined as earnings from continuing
More informationAGILENT TECHNOLOGIES, INC. CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) (Unaudited)
CONDENSED CONSOLIDATED STATEMENT OF OPERATIONS (In millions, except per share amounts) Three Months Ended January 31, Percent 2003 2002 Inc/(Dec) Orders $ 1,358 $ 1,465 (7%) Net revenue $ 1,412 $ 1,426
More informationReceivables 212, ,296 Less allowance for doubtful receivables 4,408 4,407 Net receivables 208, ,889
CONSOLIDATED BALANCE SHEETS (Amounts in thousands) March 31, December 31, ASSETS 2017 2016 Current assets: Cash and cash equivalents $ 14,759 19,297 Receivables 212,585 184,296 Less allowance for doubtful
More informationGILAT SATELLITE NETWORKS LTD. CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS U.S. dollars in thousands (except share and per share data)
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (except share and per share data) 2016 2015 2016 2015 Audited Revenues $ 279,551 $ 197,543 $ 80,345 $ 67,682 Cost of revenues 204,061 143,318 56,147 47,181
More informationVISHAY INTERTECHNOLOGY, INC. Summary of Operations (Unaudited - In thousands, except per share amounts)
Summary of Operations (Unaudited - In thousands, except per share amounts) Fiscal quarters ended June 30, 2018 March 31, 2018 July 1, 2017* Net revenues $ 761,030 $ 716,795 $ 643,164 Costs of products
More informationRevenues $ 130,168 $ 120,563 $ 66,237 $ 67,898 Cost of revenues 93,258 92,984 46,668 52,717. Gross profit 36,910 27,579 19,569 15,181
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS (except share and per share data) June 30, June 30, 2017 2016 2017 2016 Revenues $ 130,168 $ 120,563 $ 66,237 $ 67,898 Cost of revenues 93,258 92,984 46,668
More informationPOU CHEN CORPORATION AND SUBSIDIARIES
CONSOLIDATED BALANCE SHEETS March 31, 2013 December 31, 2012 March 31, 2012 January 1, 2012 ASSETS Amount % Amount % Amount % Amount % CURRENT ASSETS Cash and cash equivalents (Notes 4 and 6) $ 29,346,249
More informationHoneywell International Inc. Consolidated Statement of Operations (Unaudited) (Dollars in millions, except per share amounts)
Honeywell Q1'17 Results - 5 Consolidated Statement of Operations (Unaudited) (Dollars in millions, except per share amounts) Product sales... Service sales... Net sales... Costs, expenses and other Cost
More informationAlphabet Inc. CONSOLIDATED BALANCE SHEETS (In millions, except share amounts which are reflected in thousands and par value)
Assets Current assets: Alphabet Inc. CONSOLIDATED BALANCE SHEETS (In millions, except share amounts which are reflected in thousands and par value) As of December 31, 2015 As of December 31, 2016 (unaudited)
More informationConsolidated Balance Sheets (U.S. Dollars in thousands) December 31, 2014
Consolidated Balance Sheets (Audited) Current assets Cash and cash equivalents 44,979 33,744 Available-for-sale marketable securities 29,448 16,003 Short-term bank deposits 29,989 80,922 Trade receivables,
More informationUNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C FORM 8-K/A
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of Earliest
More informationSilicon Laboratories Inc. Condensed Consolidated Statements of Income (In thousands, except per share data) (Unaudited)
Condensed Consolidated Statements of Income Nine Months Ended Revenues $119,100 $120,154 $364,933 $381,450 Cost of revenues 46,203 41,484 143,666 128,297 Gross margin 72,897 78,670 221,267 253,153 Operating
More informationVISHAY INTERTECHNOLOGY, INC. Summary of Operations (Unaudited - In thousands, except per share amounts)
Summary of Operations (Unaudited - In thousands, except per share amounts) December 31, 2018 December 31, 2017* Net revenues $ 3,034,689 $ 2,599,368 Costs of products sold 2,146,165 1,896,259 Gross profit
More informationASSETS Amount % Amount % LIABILITIES AND STOCKHOLDERS EQUITY Amount % Amount %
BALANCE SHEETS March 31, 2011 AND 2010 ASSETS Amount % Amount % LIABILITIES AND STOCKHOLDERS EQUITY Amount % Amount % CURRENT ASSETS CURRENT LIABILITIES Cash and cash equivalents $ 715,241 1 $ 748,927
More informationHoughton Mifflin Harcourt Company Consolidated Balance Sheets
Consolidated Balance Sheets (in thousands of dollars, except share information) 2017 2016 Assets Current assets Cash and cash equivalents $ 148,979 $ 226,102 Short-term investments 86,449 80,841 Accounts
More informationinc.jet Holding, Inc Condensed Consolidated Financial Statements (Unaudited) Interim Periods Ended June 30, 2018 and 2017
inc.jet Holding, Inc Condensed Consolidated Financial Statements Interim Periods Ended June 30, 2018 and 2017 inc.jet Holding, Inc. CONDENSED CONSOLIDATED BALANCE SHEETS (dollar amounts in thousands, except
More informationJABIL CIRCUIT, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS (in thousands)
CONDENSED CONSOLIDATED BALANCE SHEETS February 28, 2015 August 31, 2014 ASSETS Current assets: Cash and cash equivalents $ 966,414 $ 1,000,249 Accounts receivable, net 1,269,171 1,208,516 Inventories 2,105,183
More informationAccounting Title 2014/3/ /12/ /3/31 Balance Sheet
Financial Statement Balance Sheet Accounting Title 2014/3/31 2013/12/31 2013/3/31 Balance Sheet Assets Current assets Cash and cash equivalents Total cash and cash equivalents 7,974,989 6,997,862 6,433,466
More informationFinancial Section. 57 Consolidated Balance Sheets. 59 Consolidated Statements of Operations. 60 Consolidated Statements of Comprehensive Income
Financial Section 57 Consolidated Balance Sheets 59 Consolidated Statements of Operations 60 Consolidated Statements of Comprehensive Income 61 Consolidated Statements of Changes in Net Assets 63 Consolidated
More informationEMERSON AND SUBSIDIARIES CONSOLIDATED OPERATING RESULTS (AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED)
CONSOLIDATED OPERATING RESULTS (AMOUNTS IN MILLIONS EXCEPT PER SHARE, UNAUDITED) Table 1 Quarter Ended March 31 Percent Change Net sales $3,579 $3,574 % Costs and expenses: Cost of sales 2,037 2,017 SG&A
More informationUNISYS CORPORATION CONSOLIDATED STATEMENTS OF INCOME (Unaudited) (Millions, except per share data)
CONSOLIDATED STATEMENTS OF INCOME (Millions, except per share data) Three Months Nine Months Ended September 30 Ended September 30 2012 2011 2012 2011 Revenue Services $748.0 $876.3 $2,386.7 $2,519.3 Technology
More informationHoneywell International Inc. Consolidated Statement of Operations (Unaudited) (In millions, except per share amounts)
Q1'13 Results - 5 Consolidated Statement of Operations (Unaudited) (In millions, except per share amounts) 2013 2012 Product sales... Service sales... Net sales... Costs, expenses and other Cost of products
More informationCOMET achieves marked double-digit growth, with improved profitability
Press Release COMET achieves marked double-digit growth, with improved profitability F l a m a t t, Switzerland August 23, 2007 The COMET Group, a world-leading manufacturer of components and systems for
More informationLABCORP ANNOUNCES 2018 SECOND QUARTER RESULTS AND UPDATES 2018 GUIDANCE
FOR IMMEDIATE RELEASE Contact: Scott Frommer (investors) 336-436-5076 Investor@labcorp.com Pattie Kushner (media) 336-436-8263 Media@labcorp.com LABCORP ANNOUNCES 2018 SECOND QUARTER RESULTS AND UPDATES
More informationConsolidated Statement of Income (unaudited)
Deutsche Bank Consolidated Financial Statements 79 Interim Report as of September 0, 05 Consolidated Statement of Income (unaudited) Consolidated Statement of Income (unaudited) Income Statement Three
More informationServiceNow, Inc. Condensed Consolidated Statements of Operations (in thousands, except share and per share data) (Unaudited)
Condensed Consolidated Statements of Operations (in thousands, except share and per share data) Revenues: Subscription $ 179,907 $ 117,375 Professional services and other 32,057 21,715 Total revenues 211,964
More informationEXALENZ BIOSCIENCE LTD.
CONSOLIDATED BALANCE SHEETS ASSETS December 31, 2017 2016 *) USD in thousands CURRENT ASSETS: Cash and cash equivalents 1,631 2,384 Short-term deposits - 2,730 Trade receivables, net 2,331 665 Other accounts
More informationITURAN LOCATION AND CONTROL LTD. Consolidated Interim Financial Statements as of March 31, 2014
Consolidated Interim Financial Statements as of March 31, 2014 Consolidated Financial Statements as of March 31, 2014 Table of Contents Page Consolidated Financial Statements: Balance Sheets 2-3 Statements
More informationDividend declared per common share $ 0.07 $ $ 0.21 $ Three Months Ended December 31, Year Ended December 31, 2017
Emerald Expositions Events, Inc. Consolidated Statements of Income (Loss) and Comprehensive Income (Loss) (unaudited, dollars in millions, share data in thousands, except earnings per share data) Three
More informationITURAN LOCATION AND CONTROL LTD. Consolidated Interim Financial Statements as of March 31, 2013
Consolidated Interim Financial Statements as of March 31, 2013 Consolidated Financial Statements as of March 31, 2013 Table of Contents Page Consolidated Financial Statements: Balance Sheets 2-3 Statements
More informationEMC CORPORATION Consolidated Income Statements (in thousands, except per share amounts) Unaudited
EMC CORPORATION Consolidated Income Statements (in thousands, except per share amounts) Three Months Ended Nine Months Ended September 30, September 30, September 30, September 30, 2012 2011 2012 2011
More informationCONSOLIDATED BALANCE SHEET
CONSOLIDATED BALANCE SHEET December 31, 2018 A S S E T S CURRENT ASSETS: Cash and time deposits 51,215 Accounts receivable-trade 95,065 Inventories 5,405 Short-term loans receivable 43,021 Deferred tax
More informationUnappropriated retained earnings (accumulated deficit) Total unappropriated retained earnings (accumulated deficit) 676, ,797 Total retained ear
Financial Statement Balance Sheet Accounting Title 2014/12/31 2013/12/31 Balance Sheet Assets Current assets Cash and cash equivalents Total cash and cash equivalents 1,183,185 1,177,682 Current bond investment
More informationNORWEGIAN CRUISE LINE HOLDINGS LTD. CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except share and per share data)
CONSOLIDATED STATEMENTS OF OPERATIONS (unaudited, in thousands, except share and per share data) Revenue Passenger ticket $ 415,399 $ 346,692 $ 1,815,869 $ 1,604,563 Onboard and other 184,946 156,479 754,425
More informationQ Earnings Results Supplementary Data, Financial Tables and Non-GAAP Reconciliations
Q2 2018 Earnings Results Supplementary Data, Financial Tables and Non-GAAP Reconciliations Non-GAAP Financial Measures CyberArk believes that the use of non-gaap gross profit, non-gaap operating income
More informationNet earnings 1,2,3 $ 933 $ 904 $ 3,605 $ 3,614 Effective tax rate 19.8 % 28.1 % 28.2 % 31.3 %
Consolidated Statements of Earnings (unaudited; in millions, except per share data) Quarters Ended Dec. 3, Years Ended Dec. 3, 205 204 205 204 Net sales $ 2,97 $ 2,530 $ 46,32 $ 45,600 Cost of sales (,607)
More informationVMware, Inc. CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) (unaudited)
CONSOLIDATED STATEMENTS OF CASH FLOWS (in thousands) For the Three Months Ended For the Year Ended 2010 2009 2010 2009 Cash flows from operating activities: Net income $ 119,880 $ 56,409 $ 357,439 $ 197,098
More informationITRON, INC. CONSOLIDATED STATEMENTS OF OPERATIONS
, INC. CONSOLIDATED STATEMENTS OF OPERATIONS (Unaudited, in thousands, except per share data) Revenues $ 523,335 $ 642,477 $ 2,178,178 $ 2,434,124 Cost of revenues 359,835 449,944 1,463,031 1,687,666 Gross
More informationStatement of Earnings
audited financial statements Statement of Earnings General Electric Company and consolidated affiliates For the years ended December 31 (In millions; per-share amounts in dollars) 2009 2008 2007 Revenues
More informationSummary Financial Information Year Ended December 2003
Summary Financial Information Year Ended December 2003 ABB Ltd Summary Consolidated Income Statements 2003 2002 2003 2002 (audited) (audited) (unaudited) (unaudited) (in millions, except per share data)
More informationWuXi PharmaTech Announces First-Quarter 2013 Results
WuXi PharmaTech Announces First-Quarter 2013 Results SHANGHAI, China, May 13, 2013 /Xinhua-PRNewswire/ -- WuXi PharmaTech (Cayman) Inc. (NYSE: WX), a leading research and development outsourcing company
More information